Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, describes a trial comparing crizotinib and chemotherapy in patients with advancedALK-positive non-small cell lung cancer.
Based on single-arm phase I and phase II trials, Shaw says, it was known that crizotinib was efficacious in this space. The primary endpoint of the trial, progression-free survival, was met.
Crizotinib showed superiority with regard to progression-free survival compared with chemotherapy: 7.7 months versus 3.0 months. In addition, Shaw points out, crizotinib significantly increased response rates, from 20% to 65%. These data confirm the efficacy of crizotinib in this space.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More